Biotest AG
XETRA:BIO2
Relative Value
The Relative Value of one
BIO2
stock under the Base Case scenario is
hidden
EUR.
Compared to the current market price of 43.02 EUR,
Biotest AG
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
BIO2 Competitors Multiples
Biotest AG Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
|
Biotest AG
XETRA:BIO2
|
1.6B EUR | 2.5 | -64.9 | 182.4 | 182.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
412.7B USD | 6.7 | 98.6 | 16.1 | 22.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
206.6B USD | 5.6 | 26.8 | 15.3 | 15.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
186.2B USD | 6.3 | 21.9 | 13.6 | 16.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
123.6B USD | 10.3 | 31.3 | 23.6 | 24.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.1B USD | 5.8 | 18.5 | 14 | 15.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70B AUD | 3.2 | 35.5 | 11.7 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40B EUR | 11.4 | 36.6 | 39.9 | 40.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |